Cencora reorganizes reporting segments ahead of fiscal 2027
Cencora will report three operating segments from fiscal 2027 and supplies revised 2025–2026 comparisons.
Cencora said on November 4 that it has reorganized its operating model and will change its reportable segments beginning in the first quarter of fiscal 2027. The company said the restructuring is intended to strengthen execution and improve visibility into its growth priorities.
The new structure will comprise Pharmaceutical Distribution and Services; Specialty Pharmaceutical and Provider Services; and Other. The first segment will include U.S. and international wholesale distribution and related services. The second will include specialty distribution for physician practices, management services organizations, World Courier, third-party logistics, Innomar and strategic components of PharmaLex.
Other will continue to include businesses for which Cencora is exploring strategic alternatives, including MWI Animal Health, Profarma and other components of PharmaLex. The company furnished revised unaudited segment information for fiscal 2025 and 2026 so investors can compare the business under the new structure.
FY26 revenue
$337.4B
↑ +5.0% revised presentation
FY26 segment operating income
$4.81B
↑ +14.0% revised presentation
Sources
This story describes figures the company has published. It is for information only and is not investment advice or a recommendation to buy, sell or hold any security. Check the original filings before relying on any figure. Stoqly is not affiliated with the SEC or Cencora.
